a 2018

Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ et. al.

Basic information

Original name

Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression

Name in Czech

Epigenetická screening léčiva na buňkách rezistentních na rituximab ukázala v neočekávané úloze inhibitorů Aurora kinázy v expresi CD20

Authors

KOZLOVÁ, Veronika (203 Czech Republic, belonging to the institution), Aneta LEDEREROVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution)

Edition

2018

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

10606 Microbiology

Confidentiality degree

is not subject to a state or trade secret

RIV identification code

RIV/00216224:14740/18:00104991

Organization unit

Central European Institute of Technology

Keywords in English

Aurora; CD20; CLL; monoclonal

Tags

Changed: 26/3/2019 15:41, Mgr. Pavla Foltynová, Ph.D.

Abstract

ORIG CZ

V originále

Epigenetic drug screen on rituximab-resistant cells revealed an unexpected role of Aurora kinase inhibitors in CD20 expression, Epigenetic drug screen on rituximab-resistant cells revealed an unexpected role of Aurora kinase inhibitors in CD20 expression.

In Czech

Epigenetická screening léčiva na buňkách rezistentních na rituximab ukázala v neočekávané úloze inhibitorů Aurora kinázy v expresi CD20, Epigenetická screening léčiva na buňkách rezistentních na rituximab ukázala v neočekávané úloze inhibitorů Aurora kinázy v expresi CD20.

Links

LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/0968/2017, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V)
Investor: Masaryk University, Category A
NV15-33561A, research and development project
Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie